Previous 10 | Next 10 |
home / stock / ucbjy / ucbjy news
BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis PR Newswire BIMZELX ® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved for the treatment of adults with moderate-to-severe plaque p...
UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis PR Newswire FDA approval of ZILBRYSQ ® (zilucoplan) has been granted for the treatment of generalized myasthenia gravis (gMG) in adult pa...
UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023 PR Newswire Results from the Phase 3 studies evaluating impact of bimekizumab on pain and health-related quality of life in moderate-to-severe hidradenitis suppurativa will ...
Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa PR Newswire Bimekizumab treatment resulted in clinically meaningful improvements in HiSCR50 and the more stringent endpoints HiSCR75, HiSCR...
2023-09-15 11:05:45 ET More on Lilly, Ascendis, and Novartis Eli Lilly: A Potential Game Changer For Weight Management And Cardiovascular Health Ascendis Pharma: Revenue Promise Meets Cash Flow Challenge Sandoz to commercialize biosimilar to J&J blockbuster drug ...
UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. PR Newswire RYSTIGGO...
UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis PR Newswire FDA approval of RYSTIGGO ® (rozanolixizumab-noli) has been granted under the Priority Review designation for the treat...
2023-06-05 05:02:09 ET Summary ClearPoint Neuro's progress on its four-pillar strategy continues despite a challenging operating environment, with an increasing number of partners and hospital sites featuring its equipment. The company has entered into pre-clinical work and milest...
UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting PR Newswire New insights from leading portfolio demonstrate ongoing commitment to improving outcomes and experiences of those living with epilepsy and rare epilep...
UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance PR Newswire ATLANTA , April 17, 2023 /PRNewswire/ -- UCB (Euronext: UCB), a global biopharmaceutical company, today announced the U...
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia PR Newswire FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of ...
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels PR Newswire Pharmacokinetic data from the CHERISH study suggest that pregnant women treated with certolizumab pegol can ...
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 PR Newswire Patients with non-radiographic axial spondyloarthritis (nr-axSpA) and those with ankylosing spondylitis (AS) treated ...